John Lee
2022 - Decibel Therapeutics
In 2022, John Lee earned a total compensation of $733.2K as Executive Vice President, Chief Development Officer at Decibel Therapeutics, a 10% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $134,100 |
|---|---|
| Option Awards | $137,004 |
| Salary | $447,015 |
| Other | $15,038 |
| Total | $733,157 |
Lee received $447K in salary, accounting for 61% of the total pay in 2022.
Lee also received $134.1K in non-equity incentive plan, $137K in option awards and $15K in other compensation.
Rankings
In 2022, John Lee's compensation ranked 3,684th out of 5,760 executives tracked by ExecPay. In other words, Lee earned more than 36.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,684 out of 5,760 | 36th |
Division Manufacturing | 2,094 out of 3,136 | 33rd |
Major group Chemicals And Allied Products | 1,011 out of 1,422 | 29th |
Industry group Drugs | 948 out of 1,323 | 28th |
Industry Pharmaceutical Preparations | 693 out of 969 | 29th |
Source: SEC filing on April 28, 2023.
Lee's colleagues
We found three more compensation records of executives who worked with John Lee at Decibel Therapeutics in 2022.
News
Marathon Patent Group CFO Hugh Gallagher receives $4.8M in 2022
June 23, 2023
Decibel Therapeutics CEO Laurence Reid's 2022 pay jumps 54% to $1.2M
April 28, 2023
PhaseBio Pharmaceuticals CEO Jonathan Mow's 2021 pay slips 13% to $1.5M
April 22, 2022
PhaseBio Pharmaceuticals CEO Jonathan Mow's 2019 pay jumps 102% to $1.2M
April 24, 2020
PhaseBio Pharmaceuticals CEO Jonathan Mow's 2018 pay jumps 37% to $596K
April 5, 2019